Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 16,507 as of Monday, Aug. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,334 issues advancing vs. 1,665 declining with 161 unchanged. The Health Services industry currently sits down 0.2% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Alere ( ALR), down 13.3%, and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.2%. Top gainers within the industry include Grifols ( GRFS), up 1.3%, Humana ( HUM), up 0.9%, Edwards Lifesciences ( EW), up 1.1%, CR Bard ( BCR), up 0.9% and Boston Scientific ( BSX), up 0.8%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Catamaran ( CTRX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Catamaran is down $1.15 (-2.6%) to $43.74 on heavy volume. Thus far, 1.3 million shares of Catamaran exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $42.96-$44.83 after having opened the day at $44.75 as compared to the previous trading day's close of $44.89. Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $9.4 billion and is part of the health care sector. Shares are down 5.4% year-to-date as of the close of trading on Friday. Currently there are 13 analysts that rate Catamaran a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Catamaran Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.